Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1621 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 12 February 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] The company have advised that they will not be pursuing a Marketing Authorisation Application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes. |
| 05 September 2019 | In progress. Referred 29 April 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual